Company Profile

  1. You are here:    Home
  2. Search Databases
  3. Search Company Registry
  4. Company Profile

Pamdeca LLC
Profile last edited on: 5/29/2021      CAGE: 7AU60      UEI: KLM1F8DQJKN1

Business Identifier: Ovarian cancer drug which activates a cancer-killing program in tumor-associated macrophages.
Year Founded
2015
First Award
2018
Latest Award
2018
Program Status
Inactive
Popularity Index

Edit Company Profile

Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.
  Explanation Edit

Location Information

105 Auburn Street
Newton, MA 02466
   (617) 872-0639
   N/A
   www.pamdeca.com
Location: Single
Congr. District: 04
County: Middlesex

Public Profile

Spun out of Northwestern University,Pamdeca LLC is working on a novel ovarian cancer drug which activates a cancer-killing program in tumor-associated macrophages. The firm is at a Proof-of-Principle stage; its drug candidates have demonstrated strong anticancer effects in three ovarian cancer animal models. They are based on innovative IP licensed from Northwestern University. The initial use of our novel therapeutic agents will be as companion drugs for immune checkpoint inhibitors.

Extent of SBIR involvement

User Avatar
Phase I Awards
1
Phase II Awards
0
Conversion Rate
0.00%
Phase I Dollars
$296,740
Phase II Dollars
$0
Total Awarded
$296,740

Synopsis: Awardee Business Condition

Employee Range
1-4
Revenue Range
Less than .5M
VC funded?
No
Public/Private
Privately Held
Stock Info
----
IP Holdings
N/A

Awards Distribution by Agency

Most Recent SBIR Projects
Year Phase Agency Total Amount
2018 1 NIH $296,740
Project Title: Development of a First-In-Class, Potent and Safe, Small Synthetic Anti-Angiogenic Peptide for Treatment of Retinopathy of Prematurity

Key People / Management

  Victor Shifrin -- CEO

  Jack Henkin -- CSO

  Olga Volpert -- Head of R&D

Company News

There are no news available.